

Mathieu Rouanne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8603351/publications.pdf>

Version: 2024-02-01

54
papers

4,283
citations

331259

21
h-index

189595

50
g-index

57
all docs

57
docs citations

57
times ranked

5334
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	0.9	1,241
2	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	0.9	1,152
3	Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. <i>BJU International</i> , 2011, 107, 1411-1418.	1.3	278
4	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	3.9	222
5	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>European Urology</i> , 2019, 75, 423-432.	0.9	205
6	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	12.8	150
7	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 589-594.	1.4	125
8	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
9	Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. <i>BJU International</i> , 2017, 120, 12-24.	1.3	63
10	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	2.6	61
11	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. <i>European Urology Oncology</i> , 2020, 3, 728-738.	2.6	61
12	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. <i>European Radiology</i> , 2019, 29, 4286-4293.	2.3	48
13	Novel therapeutic targets in advanced urothelial carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 106-115.	2.0	45
14	c-Met activation leads to the establishment of a TGF β 2-receptor regulatory network in bladder cancer progression. <i>Nature Communications</i> , 2019, 10, 4349.	5.8	44
15	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	1.3	42
16	Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. <i>European Journal of Cancer</i> , 2013, 49, 431-438.	1.3	41
17	Long-Term Women-Reported Quality of Life After Radical Cystectomy and Orthotopic Ileal Neobladder Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 1398-1404.	0.7	32
18	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 483.	1.1	31

#	ARTICLE	IF	CITATIONS
19	European Association of Urology Guidelines on Primary Urethral Carcinomaâ€”2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	2.6	28
20	Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1724-1730.	0.5	27
21	Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed nonâ€”muscle-invasive bladder cancer with positive results on urine cytology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1135-1140.	0.8	25
22	Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1008-1013.	0.7	24
23	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. <i>Hormones and Cancer</i> , 2019, 10, 36-44.	4.9	23
24	The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 565086.	1.3	20
25	Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: Ten years of follow-up. <i>Scandinavian Journal of Urology</i> , 2014, 48, 131-137.	0.6	19
26	Trends in Renal Function After Radical Cystectomy and Ileal Conduit Diversion: New Insights Regarding Estimated Glomerular Filtration Rate Variations. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e139-e144.	0.9	18
27	Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) nonâ€”muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. <i>PLoS ONE</i> , 2019, 14, e0211721.	1.1	17
28	Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies. , 2020, 8, e000579.		17
29	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	1.3	16
30	Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score. <i>Urologia Internationalis</i> , 2017, 99, 156-161.	0.6	15
31	CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer. <i>European Journal of Cancer</i> , 2021, 151, 245-248.	1.3	14
32	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. <i>World Journal of Urology</i> , 2021, 39, 1345-1355.	1.2	13
33	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	11
34	Value of positron emission tomography in diagnosing synchronous penile metastasis from urothelial bladder cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 276.	0.8	9
35	Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial). <i>Prostate</i> , 2019, 79, 272-280.	1.2	9
36	Immunodynamics of explanted human tumors for immunoâ€”oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2015, 7, 125-134.	0.9	8
38	Inclusion of Patients With Advanced Cancer in Phase I Trials: Is This a Tool for Improving Optimism and Emotional Well-Being?. <i>Journal of Clinical Oncology</i> , 2013, 31, 817-818.	0.8	7
39	Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. <i>Cancer Discovery</i> , 2020, 10, 1097-1099.	7.7	7
40	Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 12.e1-12.e11.	0.8	6
41	Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16145.	1.6	5
42	Reply to Pontus Eriksson and Gottfrid Sjöndahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. <i>Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol</i> 2019;75:423-432. <i>European Urology</i> , 2019, 75, e108-e109.	0.9	4
43	Management of Renal Cell Carcinoma in Sigmoid Kidney. <i>Urologia Internationalis</i> , 2012, 88, 483-485.	0.6	2
44	Parotid gland metastasis from prostate cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 367-370.	0.7	2
45	Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1212-1213.	3.3	2
46	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. <i>Asian Journal of Andrology</i> , 2021, 23, 520.	0.8	2
47	Re: Xiao-Dong Jin, Simone Roethlisberger, Fiona C. Burkhard, Frédéric Birkhaeuser, Harriet C. Thoeny, Urs E. Studer. Long-term Renal Function After Urinary Diversion by Ileal Conduit or Orthotopic Ileal Bladder Substitution. <i>Eur Urol</i> 2012;61:491-497. <i>European Urology</i> , 2012, 62, e55-e56.	0.9	1
48	1416 ARE WE EVALUATING PROPERLY THE RENAL FUNCTION WITH THE MODIFICATION OF DIET IN RENAL DISEASE (MDRD) IN PATIENTS WITH ORTHOTOPIC ILEAL NEOBLADDER?. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
49	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. <i>Asian Journal of Andrology</i> , 2021, 23, 370.	0.8	1
50	Re: Long-Term Renal Function Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2015, 193, 1066-1067.	0.2	0
51	Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2018, 199, 854-856.	0.2	0
52	Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 139-141.	0.8	0
53	Utility of Routine Preoperative 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Letter.. <i>Journal of Urology</i> , 2021, 206, 169-170.	0.2	0
54	Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals. <i>European Journal of Cancer</i> , 2022, 162, 130-132.	1.3	0